ADC 접합 키트 — 빠르고 정밀하며 신뢰성을 갖춘 접합

Figure 1. The ADC was prepared using the ADC Conjugation Kit (MMAE, DAR4) and analyzed by HIC and SEC-HPLC. The average drug-antibody ratio (DAR) is 4.0±0.5, and the purity of the ADC is greater than 95%.

Figure 2. The DAR (3.82) was calculated from the weighted average of the deconvoluted MS peak areas using LC-MS/MS. The results showed the deconvoluted mass spectra of light chains and heavy chains, and the increase in molecular weight caused by the conjugated payload (1316±3 Da). The heterogeneity in N-glycosylation of heavy chain adds to the complexity of the mass spectrum.

Figure 3. Binding affinity of anti-Her2 antibody and anti-Her2 antibody–MMAE conjugate to human Her2 (Cat. No. HE2-H5225) as determined by BLI (Bio-Layer Interferometry). The conjugate exhibits nanomolar affinity (0.57 nM) for human Her2, comparable to the naked antibody (0.86 nM).

Figure 4. In vitro cytotoxicity assays: The ADC can bind and internalize in target cells (SK-BR-3) with high expression of Her2 and release MMAE inside the cells to induce a cytotoxic effect (IC₅₀=0.0058 µg/mL). Meanwhile, no cytotoxicity was observed in Her2 receptor-negative cell lines (MDA-MB-231).

Figure 5. In vitro cytotoxicity of products prepared by different size of the ADC Conjugation Kit (Cat. No. ADC-P013, ADC-P014). The result shows very high consistency (RSD＜10%).

Figure 6. The MMAE-ADC was prepared using the ADC Conjugation Kit, which were left at 37℃ for 21 days. The ADCs were analyzed by HIC and SEC-HPLC. The average drug-antibody ratio (DAR) is 4.0±0.5, and the purity of the ADC is greater than 95%.